(877) 320-5131 Menu
(877) 320-5131
Contact
Patient Portal

Recruiting

GSK: A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC):


Pfizer C3441021 - TALAPRO: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYOF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATICCASTRATION-RESISTANT PROSTATE CANCER


"ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer"


Upcoming

Pfizer: (EZH2): 235999: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITHRELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULARLYMPHOMA (FL):

For more information about Beverly Hills Cancer Center's comprehensive clinical research programs and trials currently available to patients, please contact us at (310) 432-8932 or click here to send in an inquiry.

Schedule a Consultation

Your health is important, and we welcome the opportunity to help you heal.


To schedule an appointment, please call Beverly Hills Cancer Center in Beverly Hills, California at (877) 320-5131 or Click the link below to access our Online Appointment Request

Book An Appointment

© Beverly Hills Cancer Center. All Rights Reserved. Web Design & Internet Marketing by Studio III

Privacy Policy

Rate Us
Rate us on Google Rate us on Yelp Rate us on HealthGrades Rate us on Facebook Rate us on Yahoo! Rate us on WebMD
Contact Us